Stemline Therapeutics Inc. (NASDAQ:STML)’s share price traded up 4.4% on Monday . The stock traded as high as $7.90 and last traded at $7.80, with a volume of 192,309 shares trading hands. The stock had previously closed at $7.47.

Several equities analysts have recently weighed in on the company. Jefferies Group reiterated a “buy” rating and issued a $23.00 price target on shares of Stemline Therapeutics in a research report on Monday, June 6th. Zacks Investment Research upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a research report on Wednesday, July 6th. Wedbush reissued an “outperform” rating and set a $16.00 price objective on shares of Stemline Therapeutics in a research note on Tuesday, June 7th. Finally, Roth Capital reissued a “buy” rating and set a $32.00 price objective on shares of Stemline Therapeutics in a research note on Tuesday, May 10th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $19.56.

The stock’s 50 day moving average is $7.11 and its 200-day moving average is $5.90. The firm’s market capitalization is $137.48 million.

Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, equities research analysts expect that Stemline Therapeutics Inc. will post ($2.14) EPS for the current fiscal year.

An institutional investor recently raised its position in Stemline Therapeutics stock. Royce & Associates LLC boosted its stake in shares of Stemline Therapeutics Inc. (NASDAQ:STML) by 318.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 159,179 shares of the biopharmaceutical company’s stock after buying an additional 121,179 shares during the period. Royce & Associates LLC owned approximately 0.91% of Stemline Therapeutics worth $1,004,000 as of its most recent filing with the SEC.

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.